merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>safety risks</answer>

<question_number>2</question_number>
<answer>slow progress</answer>

<question_number>3</question_number>
<answer>no correlation</answer>

<question_number>4</question_number>
<answer>higher safety risks</answer>

<question_number>5</question_number>
<answer>patients can stop after amyloid cleared</answer>

<question_number>6</question_number>
<answer>discourage participation</answer>

<question_number>7</question_number>
<answer>stop after amyloid cleared</answer>

<question_number>8</question_number>
<answer>amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>intermediate tau levels</answer>